Efficacy and safety of dose escalation in male patients with overactive bladder showing poor efficacy after low-dose antimuscarinic treatment: A retrospective multicenter study
Purpose: To analyze the efficacy and safety of standard-dose antimuscarinic treatment on male patients with overactive bladder (OAB) symptoms showing poor efficacy after low-dose antimuscarinics. Materials and Methods: We retrospectively reviewed the data of 566 male patients aged ≥40 with OAB sympt...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Korean Urological Association
2020-11-01
|
| Series: | Investigative and Clinical Urology |
| Subjects: | |
| Online Access: | https://www.icurology.org/Synapse/Data/PDFData/2020ICU/icu-61-600.pdf |
| _version_ | 1828467589295112192 |
|---|---|
| author | Myungsun Shim Jong Keun Kim Woo Jin Bang Yong Seong Lee Sung Tae Cho Jin Seon Cho Kwan Joong Joo Jae Seog Hyun Byung Hoon Kim Jong Bok Lee Young Jin Seo Cheol Young Oh |
| author_facet | Myungsun Shim Jong Keun Kim Woo Jin Bang Yong Seong Lee Sung Tae Cho Jin Seon Cho Kwan Joong Joo Jae Seog Hyun Byung Hoon Kim Jong Bok Lee Young Jin Seo Cheol Young Oh |
| author_sort | Myungsun Shim |
| collection | DOAJ |
| description | Purpose: To analyze the efficacy and safety of standard-dose antimuscarinic treatment on male patients with overactive bladder (OAB) symptoms showing poor efficacy after low-dose antimuscarinics. Materials and Methods: We retrospectively reviewed the data of 566 male patients aged ≥40 with OAB symptoms between January 2017 and June 2018. They were treated with low-dose antimuscarinics for at least 4 weeks and showed poor efficacy; therefore, they were switched to standard dose antimuscarinic treatment (5 mg of solifenacin) for ≥12 weeks. The international prostate symptom score (IPSS) and overactive bladder symptom score (OABSS) at baseline (V0), 4 weeks (V1), and 12 weeks (V2) were analyzed. Post void residual urine volume (PVR) was also recorded. Results: The median age, body mass index, and prostate-specific antigen levels were 69.0 years, 24.2 kg/m2, and 1.24 ng/dL, respectively. The mean value of the total IPSS and OABSS significantly decreased between V0 and V2 (from 16.73 to 13.69 and 7.33 to 5.34, respectively, all p<0.001). All component scores from each questionnaire demonstrated a significant decrease except for numbers three and six on the IPSS questionnaire. PVR was increased from V0 to V2 (36.40 to 68.90 mL, p=0.015). Four and nine patients experienced constipation and thirst, respectively, and all adverse effects were graded as ≤2. Conclusions: Standard dose antimuscarinic treatment using solifenacin (5 mg) may be a safe and effective treatment for patients with OAB symptoms refractory to low-dose antimuscarinic treatment. |
| first_indexed | 2024-12-11T04:09:11Z |
| format | Article |
| id | doaj.art-3e8ba4010dec48928522c37ca0978481 |
| institution | Directory Open Access Journal |
| issn | 2466-0493 2466-054X |
| language | English |
| last_indexed | 2024-12-11T04:09:11Z |
| publishDate | 2020-11-01 |
| publisher | Korean Urological Association |
| record_format | Article |
| series | Investigative and Clinical Urology |
| spelling | doaj.art-3e8ba4010dec48928522c37ca09784812022-12-22T01:21:27ZengKorean Urological AssociationInvestigative and Clinical Urology2466-04932466-054X2020-11-0161660060610.4111/icu.20200053Efficacy and safety of dose escalation in male patients with overactive bladder showing poor efficacy after low-dose antimuscarinic treatment: A retrospective multicenter studyMyungsun Shim0https://orcid.org/0000-0003-2029-9081Jong Keun Kim1https://orcid.org/0000-0001-6507-2628Woo Jin Bang2Yong Seong Lee3https://orcid.org/0000-0003-0611-4554Sung Tae Cho4https://orcid.org/0000-0002-4691-6159Jin Seon Cho5https://orcid.org/0000-0003-0429-191XKwan Joong Joo6Jae Seog Hyun7Byung Hoon Kim8Jong Bok Lee9Young Jin Seo10https://orcid.org/0000-0002-9114-8363Cheol Young Oh11https://orcid.org/0000-0001-8794-1855Department of Urology, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea.Department of Urology, Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Hwaseong, Korea.Department of Urology, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea.Department of Urology, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea.Department of Urology, Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea.Department of Urology, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea.Department of Urology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.Department of Urology, Gyeongsang National University School of Medicine, Jinju, Korea.Department of Urology, Keimyung University School of Medicine, Daegu, Korea.Department of Urology, National Medical Center, Seoul, Korea.Department of Urology, Dongguk University College of Medicine, Gyeongju, Korea.Department of Urology, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea.Purpose: To analyze the efficacy and safety of standard-dose antimuscarinic treatment on male patients with overactive bladder (OAB) symptoms showing poor efficacy after low-dose antimuscarinics. Materials and Methods: We retrospectively reviewed the data of 566 male patients aged ≥40 with OAB symptoms between January 2017 and June 2018. They were treated with low-dose antimuscarinics for at least 4 weeks and showed poor efficacy; therefore, they were switched to standard dose antimuscarinic treatment (5 mg of solifenacin) for ≥12 weeks. The international prostate symptom score (IPSS) and overactive bladder symptom score (OABSS) at baseline (V0), 4 weeks (V1), and 12 weeks (V2) were analyzed. Post void residual urine volume (PVR) was also recorded. Results: The median age, body mass index, and prostate-specific antigen levels were 69.0 years, 24.2 kg/m2, and 1.24 ng/dL, respectively. The mean value of the total IPSS and OABSS significantly decreased between V0 and V2 (from 16.73 to 13.69 and 7.33 to 5.34, respectively, all p<0.001). All component scores from each questionnaire demonstrated a significant decrease except for numbers three and six on the IPSS questionnaire. PVR was increased from V0 to V2 (36.40 to 68.90 mL, p=0.015). Four and nine patients experienced constipation and thirst, respectively, and all adverse effects were graded as ≤2. Conclusions: Standard dose antimuscarinic treatment using solifenacin (5 mg) may be a safe and effective treatment for patients with OAB symptoms refractory to low-dose antimuscarinic treatment.https://www.icurology.org/Synapse/Data/PDFData/2020ICU/icu-61-600.pdfmuscarinic antagonistsprostatic hyperplasiatreatment outcomeurinary bladderoveractive |
| spellingShingle | Myungsun Shim Jong Keun Kim Woo Jin Bang Yong Seong Lee Sung Tae Cho Jin Seon Cho Kwan Joong Joo Jae Seog Hyun Byung Hoon Kim Jong Bok Lee Young Jin Seo Cheol Young Oh Efficacy and safety of dose escalation in male patients with overactive bladder showing poor efficacy after low-dose antimuscarinic treatment: A retrospective multicenter study Investigative and Clinical Urology muscarinic antagonists prostatic hyperplasia treatment outcome urinary bladder overactive |
| title | Efficacy and safety of dose escalation in male patients with overactive bladder showing poor efficacy after low-dose antimuscarinic treatment: A retrospective multicenter study |
| title_full | Efficacy and safety of dose escalation in male patients with overactive bladder showing poor efficacy after low-dose antimuscarinic treatment: A retrospective multicenter study |
| title_fullStr | Efficacy and safety of dose escalation in male patients with overactive bladder showing poor efficacy after low-dose antimuscarinic treatment: A retrospective multicenter study |
| title_full_unstemmed | Efficacy and safety of dose escalation in male patients with overactive bladder showing poor efficacy after low-dose antimuscarinic treatment: A retrospective multicenter study |
| title_short | Efficacy and safety of dose escalation in male patients with overactive bladder showing poor efficacy after low-dose antimuscarinic treatment: A retrospective multicenter study |
| title_sort | efficacy and safety of dose escalation in male patients with overactive bladder showing poor efficacy after low dose antimuscarinic treatment a retrospective multicenter study |
| topic | muscarinic antagonists prostatic hyperplasia treatment outcome urinary bladder overactive |
| url | https://www.icurology.org/Synapse/Data/PDFData/2020ICU/icu-61-600.pdf |
| work_keys_str_mv | AT myungsunshim efficacyandsafetyofdoseescalationinmalepatientswithoveractivebladdershowingpoorefficacyafterlowdoseantimuscarinictreatmentaretrospectivemulticenterstudy AT jongkeunkim efficacyandsafetyofdoseescalationinmalepatientswithoveractivebladdershowingpoorefficacyafterlowdoseantimuscarinictreatmentaretrospectivemulticenterstudy AT woojinbang efficacyandsafetyofdoseescalationinmalepatientswithoveractivebladdershowingpoorefficacyafterlowdoseantimuscarinictreatmentaretrospectivemulticenterstudy AT yongseonglee efficacyandsafetyofdoseescalationinmalepatientswithoveractivebladdershowingpoorefficacyafterlowdoseantimuscarinictreatmentaretrospectivemulticenterstudy AT sungtaecho efficacyandsafetyofdoseescalationinmalepatientswithoveractivebladdershowingpoorefficacyafterlowdoseantimuscarinictreatmentaretrospectivemulticenterstudy AT jinseoncho efficacyandsafetyofdoseescalationinmalepatientswithoveractivebladdershowingpoorefficacyafterlowdoseantimuscarinictreatmentaretrospectivemulticenterstudy AT kwanjoongjoo efficacyandsafetyofdoseescalationinmalepatientswithoveractivebladdershowingpoorefficacyafterlowdoseantimuscarinictreatmentaretrospectivemulticenterstudy AT jaeseoghyun efficacyandsafetyofdoseescalationinmalepatientswithoveractivebladdershowingpoorefficacyafterlowdoseantimuscarinictreatmentaretrospectivemulticenterstudy AT byunghoonkim efficacyandsafetyofdoseescalationinmalepatientswithoveractivebladdershowingpoorefficacyafterlowdoseantimuscarinictreatmentaretrospectivemulticenterstudy AT jongboklee efficacyandsafetyofdoseescalationinmalepatientswithoveractivebladdershowingpoorefficacyafterlowdoseantimuscarinictreatmentaretrospectivemulticenterstudy AT youngjinseo efficacyandsafetyofdoseescalationinmalepatientswithoveractivebladdershowingpoorefficacyafterlowdoseantimuscarinictreatmentaretrospectivemulticenterstudy AT cheolyoungoh efficacyandsafetyofdoseescalationinmalepatientswithoveractivebladdershowingpoorefficacyafterlowdoseantimuscarinictreatmentaretrospectivemulticenterstudy |